Wegovy for NASH: Off-Label Use, Evidence, and Monitoring

What Is NASH and Why the Name Changed to MASH

NASH (nonalcoholic steatohepatitis) is a progressive form of fatty liver disease marked by hepatocyte inflammation, ballooning, and varying degrees of fibrosis. In 2023, a multi-society Delphi consensus renamed it MASH (metabolic dysfunction-associated steatohepatitis) to better reflect its metabolic drivers and reduce stigma tied to the word "nonalcoholic" 1.

The Scale of the Problem

Roughly 25% of U.S. Adults have metabolic dysfunction-associated steatotic liver disease (MASLD), and an estimated 20% of those progress to MASH 2. Without intervention, MASH can advance to cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. The disease is tightly linked to obesity, insulin resistance, and type 2 diabetes.

Why GLP-1 Receptor Agonists Draw Interest

GLP-1 receptor agonists like semaglutide reduce body weight, improve insulin sensitivity, and lower systemic inflammation. These three pathways overlap directly with the metabolic forces that drive MASH progression. That overlap explains why hepatologists began studying semaglutide for fatty liver disease years before any liver-specific trial read out 3.

Wegovy's FDA-Approved Indication vs. Off-Label NASH Use

Wegovy (semaglutide 2.4 mg subcutaneous injection once weekly) received FDA approval in June 2021 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia 4. It does not carry an indication for NASH or MASH.

What "Off-Label" Means Here

Off-label prescribing is legal and common in the United States. It means a provider prescribes an FDA-approved drug for a condition, dose, or population not specified on the product label. For Wegovy and NASH, the evidence base is a single positive phase 2 randomized controlled trial plus supportive secondary analyses from the STEP weight-loss program. No phase 3 NASH-specific trial of semaglutide 2.4 mg has been completed as of May 2026.

How This Differs from Resmetirom

Resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, received accelerated FDA approval in March 2024 specifically for MASH with moderate to advanced fibrosis (stages F2-F3) 5. Resmetirom targets the liver directly. Semaglutide works systemically through weight loss and metabolic improvement. The two mechanisms are distinct, and some hepatologists are exploring combination approaches.

The Phase 2 Trial: Newsome et al. 2021

The strongest evidence for semaglutide in NASH comes from a phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in February 2021. The study enrolled 320 patients with biopsy-confirmed NASH and liver fibrosis stages F1 through F3 6.

Study Design and Doses

Participants were randomized to subcutaneous semaglutide at 0.1 mg, 0.2 mg, or 0.4 mg daily, or placebo, for 72 weeks. The primary endpoint was NASH resolution (disappearance of hepatocyte ballooning) with no worsening of fibrosis. The 0.4 mg daily dose is pharmacokinetically comparable to the weekly 2.4 mg dose used in Wegovy, though the formulations are not identical.

Key Results

In the 0.4 mg group, 59% of patients achieved NASH resolution without fibrosis worsening, compared to 17% on placebo (P<0.001) 6. ALT levels dropped by a mean of 20 U/L in the highest-dose arm. Body weight decreased by approximately 13% from baseline.

Fibrosis improvement (defined as a one-stage or greater reduction) occurred in 43% of the 0.4 mg group versus 33% of placebo recipients. That difference did not reach statistical significance. This is a critical gap: semaglutide resolved inflammation but did not clearly reverse scarring in this trial.

What the Investigators Said

Lead author Philip Newsome, MD, PhD, stated: "Semaglutide led to a significantly higher percentage of patients with NASH resolution than placebo, but the trial was not powered to detect a difference in fibrosis improvement" 6. That phrasing matters. The fibrosis result may reflect a sample-size limitation rather than a true lack of effect.

Supporting Evidence from STEP Trials and Other Analyses

The STEP clinical trial program studied semaglutide 2.4 mg weekly for obesity and produced secondary liver-related data that supports the NASH hypothesis.

STEP-1 Liver Biomarker Shifts

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo 7. A post hoc analysis showed significant reductions in ALT (a marker of hepatocyte injury) among participants with elevated baseline values. Weight loss of this magnitude independently reduces hepatic steatosis, as confirmed by MRI-PDFF substudies in similar GLP-1 trials 8.

The SELECT Cardiovascular Trial

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease 9. While SELECT did not include liver biopsy endpoints, the cardiovascular benefit is relevant because MASH patients carry elevated cardiovascular risk. The American Association for the Study of Liver Diseases (AASLD) notes that cardiovascular disease, not liver failure, is the leading cause of death in patients with MASLD 10.

ESSENCE Trial (Ongoing)

Novo Nordisk's phase 3 ESSENCE trial is evaluating semaglutide 2.4 mg weekly specifically for MASH with fibrosis. In March 2024, interim results reported that semaglutide met the primary endpoint of MASH resolution without worsening of fibrosis. Full peer-reviewed data had not been published as of May 2026 11.

Monitoring Requirements for Off-Label Wegovy in NASH

When a provider prescribes Wegovy off-label for NASH, structured monitoring is essential. The standard Wegovy label monitoring focuses on GI tolerability, heart rate, and pancreatitis risk. NASH-specific monitoring adds liver-focused assessments.

Baseline Assessment

Before initiating therapy, obtain the following:

• Liver enzymes: ALT, AST, GGT, alkaline phosphatase
• Fibrosis markers: FIB-4 index (calculated from age, ALT, AST, platelet count), and ideally a FibroScan (vibration-controlled transient elastography) or MRI-PDFF
• Metabolic panel: HbA1c, fasting glucose, fasting lipid panel, serum creatinine
• Body composition: weight, BMI, waist circumference
• Liver biopsy: considered for patients with indeterminate fibrosis staging or when the diagnosis is uncertain. The 2023 AASLD Practice Guidance states that "liver biopsy remains the reference standard for diagnosing and staging MASH" 10

During Dose Escalation (Weeks 1 Through 16)

Wegovy follows a fixed titration schedule: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each step lasting 4 weeks. During this period:

• Check ALT and AST at week 4 and week 12
• Monitor for GI side effects (nausea, vomiting, diarrhea), which peak during the first 8 to 12 weeks
• Assess for signs of pancreatitis (persistent severe abdominal pain radiating to the back)
• Record weight at each visit to track early response

Maintenance Monitoring (After Reaching 2.4 mg)

Once the patient reaches the full 2.4 mg dose, the monitoring cadence shifts:

• Every 3 months for the first year: ALT, AST, body weight, HbA1c (if diabetic or prediabetic), GI symptom check
• Every 6 months: FIB-4 recalculation, lipid panel
• Every 6 to 12 months: repeat FibroScan or MRI-PDFF to assess changes in steatosis and fibrosis
• Annually: comprehensive metabolic panel, reassessment of cardiovascular risk factors

When to Consider Repeat Liver Biopsy

Repeat biopsy is not routine but may be warranted if noninvasive markers worsen despite therapy (rising FIB-4, increasing liver stiffness on elastography), if the patient is a candidate for clinical trial enrollment requiring biopsy confirmation, or if there is clinical suspicion of disease progression to cirrhosis.

Interpreting Liver Enzyme Trends on Semaglutide

ALT is the most useful single biomarker for tracking hepatocyte injury in NASH patients on semaglutide. A meaningful response typically shows ALT declining within the first 12 to 24 weeks of treatment.

What Counts as a Response

A drop in ALT of 30% or more from baseline, or normalization below 19 U/L for women and 30 U/L for men (using the revised Prati criteria), suggests reduced liver inflammation 12. In the Newsome trial, ALT reductions were proportional to weight loss.

Red Flags That Require Escalation

An ALT rise above three times the upper limit of normal during treatment should prompt evaluation for alternative causes: drug-induced liver injury, viral hepatitis reactivation, autoimmune hepatitis flare, or biliary obstruction. Semaglutide itself is not a common hepatotoxin, but the clinical context matters. Any new-onset jaundice, coagulopathy, or encephalopathy warrants urgent hepatology referral and drug discontinuation.

Who Is a Reasonable Candidate for Off-Label Wegovy in NASH

Not every NASH patient is appropriate for off-label semaglutide. Patient selection requires weighing the evidence gaps against the metabolic profile.

Strongest Candidates

Patients most likely to benefit are those with biopsy-confirmed or noninvasively staged MASH (F1-F3 fibrosis), coexisting obesity (BMI ≥30), and features of metabolic syndrome. The presence of type 2 diabetes further strengthens the rationale, since semaglutide at lower doses (Ozempic 1.0 mg or 2.0 mg) carries an FDA-approved diabetes indication 13.

Weaker Candidates

Patients with compensated cirrhosis (F4) were excluded from the Newsome phase 2 trial, so efficacy and safety data in that population are limited. Patients with decompensated cirrhosis should not receive semaglutide due to unpredictable drug metabolism and the risk of worsening sarcopenia from rapid weight loss. Lean NASH patients (BMI <25) lack supportive trial data for weight-based GLP-1 therapy.

The AASLD Position

The 2023 AASLD Practice Guidance on MASLD acknowledges the "promising" role of GLP-1 receptor agonists for MASH but stops short of a formal recommendation pending phase 3 data. The guidance states: "GLP-1 receptor agonists may be considered in patients with MASH and coexisting type 2 diabetes or obesity, particularly when weight loss is a treatment goal" 10.

Practical Prescribing Considerations

Insurance and Cost

Wegovy's list price exceeds $1,300 per month in the United States. Insurance coverage for off-label NASH use is inconsistent. Most commercial plans cover Wegovy for obesity (BMI ≥30 or ≥27 with comorbidity), which many NASH patients already meet. Documenting the obesity diagnosis as the primary indication simplifies prior authorization. Novo Nordisk offers a savings card that can reduce copays to as little as $0 for eligible commercially insured patients 14.

Dose Adjustments and GI Tolerability

In STEP-1, 44.2% of semaglutide-treated patients reported nausea, though most episodes were mild to moderate and occurred during dose escalation 7. Extending any titration step by 2 to 4 additional weeks can improve tolerability without losing efficacy. Patients should eat small meals, avoid high-fat foods during escalation, and stay hydrated.

Duration of Therapy

No consensus exists on how long to continue semaglutide for NASH. The Newsome trial lasted 72 weeks. Weight and metabolic benefits reverse after discontinuation in most patients, as shown by the STEP-4 extension study, which found two-thirds of lost weight regained within one year of stopping semaglutide 15. This suggests that NASH patients may need ongoing therapy if the primary mechanism of benefit is sustained weight loss.

Risks and Limitations of Off-Label Use

Evidence Gaps

The phase 2 NASH trial used daily subcutaneous semaglutide at doses up to 0.4 mg, not the once-weekly 2.4 mg Wegovy formulation. While the pharmacokinetic exposure is considered comparable, the formulations have not been directly compared in a liver biopsy study. The ESSENCE phase 3 trial uses the weekly 2.4 mg formulation, but full results await peer-reviewed publication.

Fibrosis Uncertainty

Semaglutide has not yet demonstrated statistically significant fibrosis regression in a completed, fully published trial. For patients whose primary clinical concern is fibrosis (F3 or early F4), resmetirom has stronger stage-specific evidence 5. Some clinicians are combining semaglutide for metabolic improvement with resmetirom for direct antifibrotic effect, though no trial has validated this combination.

Safety Signals to Watch

Semaglutide carries labeled warnings for medullary thyroid carcinoma risk (based on rodent studies), acute pancreatitis, gallbladder disease, and acute kidney injury from dehydration secondary to GI side effects 4. In the SELECT trial, cholelithiasis occurred in 2.6% of semaglutide patients versus 2.1% on placebo. Monitoring for biliary symptoms is especially relevant in NASH patients, who already have elevated gallstone risk from rapid weight loss and metabolic dysfunction.

Patients with MASH and F2 or higher fibrosis who begin semaglutide 2.4 mg should have ALT and AST checked at weeks 4 and 12 during dose escalation, quarterly during the first year of maintenance, and FibroScan or MRI-PDFF repeated every 6 to 12 months to confirm that hepatic fat and stiffness are trending downward 10.